Boost For Oral SERDs As Menarini/Radius’ Orserdu Becomes First Approved For Breast Cancer
Following US FDA Approval
Executive Summary
The firms’ Orserdu has won a US thumbs up for the treatment of ESR1-mutated advanced or metastatic breast cancer, marking a positive breakthrough for the challenging SERD drug class.
You may also be interested in...
Olema Boosts Its Partnering Position With SERD Combo Data
Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.
Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.
Finance Watch: Novartis Sets October Separation Date For Sandoz Spin-Off
Novartis revealed detailed terms and a 4 October spin-off date for Sandoz’s standalone debut. Also, MIRA launched a small IPO, but two firms plan to go public in SPAC mergers. Also, Mirati’s $345m offering leads follow-ons offerings and Sangon Biotech raised $290m in venture capital.